Clinical Trials Logo

Ulcerative Colitis clinical trials

View clinical trials related to Ulcerative Colitis.

Filter by:

NCT ID: NCT03162432 Not yet recruiting - Ulcerative Colitis Clinical Trials

High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade

Start date: June 1, 2017
Phase: Phase 3
Study type: Interventional

The goal of this study will be to assess the safety and efficacy of high-dose interval Vitamin D3 therapy in children and young adults with Inflammatory Bowel Disease being treated with serial Remicade infusions.

NCT ID: NCT03151850 Recruiting - Ulcerative Colitis Clinical Trials

The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis

Start date: July 2016
Phase: N/A
Study type: Observational

We analyzed the diversity of the fungal and bacterial within colon mucosa between patients with different degree of inflammation of Ulcerative Colitis.

NCT ID: NCT03143517 Recruiting - Ulcerative Colitis Clinical Trials

Fecal Calprotectin Collection Protocol

CALFE
Start date: April 19, 2017
Phase: N/A
Study type: Observational

The primary objective is to obtain stool samples from subjects with symptoms of an undiagnosed gastrointestinal disorder. All subjects enrolled in the study will undergo a colonoscopy.

NCT ID: NCT03142113 Recruiting - Ulcerative Colitis Clinical Trials

Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis

CEDAR UC
Start date: November 2016
Phase: N/A
Study type: Observational

This retrospective multi-centric Belgian observational trial will involve all patients who have initiated adalimumab for moderate-to-severe ulcerative colitis prior to September 1st 2015 in a Belgian centre maintaining a prospective log of patients using biological therapy. Only patients fulfilling all Belgian reimbursement criteria for adalimumab will be included, namely having failed mesalamine and steroids or thiopurine analogues for at least 3 months, or being intolerant to this therapy, and showing a total Mayo score of at least 6 with an endoscopic sub-score of at least 2. Both short-term and long-term outcome of adalimumab therapy will be evaluated, focusing on the need and successfulness of adalimumab dose-escalation from 40mg every other week to 40mg every week, and dose de-escalation back to 40mg every other week.

NCT ID: NCT03138655 Not yet recruiting - Crohn's Disease Clinical Trials

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Start date: May 12, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active ulcerative colitis or Crohn's disease.

NCT ID: NCT03136419 Recruiting - Ulcerative Colitis Clinical Trials

Microbiota and Immune microEnvironment in Pouchitis

MEP1
Start date: October 31, 2016
Phase: N/A
Study type: Interventional

Microbiota and innate immunity in pouchitis: predisposing factors and modulation of the inflammation with probiotics. Around 20-25% of ulcerative colitis patients undergo restorative proctocolectomy with ileal pouch anal anastomosis. Pouchitis is an idiopathic inflammatory disease that may occur in ileal pouches. In our recent studies, we showed altered microbiota and innate immunity relationships in pouchitis. We plain to perform a double-blind, placebo-controlled trial probiotic therapy vs placebo starting at the time of ileostomy closure to evaluate the impact of microbiota that colonizes the pouch mucosa in the pathogenesis of pouchits, to determine how expression and activation status of the innate immunity system in different cell types and anatomical districts of pouch mucosa relate to microbiota population and follow-up the clinical outcome of anal pouches in light of microbiota-innate immune system interplay. Our study will include three phases: 1. analysis of the intestinal microbiota with High Throughput Sequencing Unit and anaerobes cultures 2. characterization of innate immunity with TLR, NLR, nicotinic receptors and LPMC analysis 3. assessment of microbiota and innate immune system in the ileal pouch before ileostomy closure, 2 months after ileostomy closure and after 1 year follow up.

NCT ID: NCT03131414 Not yet recruiting - Healthy Clinical Trials

The IMAGINE-SPOR CIHR Chronic Disease Network

IMAGINE
Start date: June 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The IMAGINE Cohort Study will identify and recruit a cohort of 8000 patients with IBS, IBD and healthy controls (2000 of each) who will be assessed in terms of their psychological status, dietary intake, gut microbiome, metabolomic and inflammatory markers and genotype, health-related quality of life, and health care resource use and associated costs. The cohort and healthy controls will be followed prospectively for up to 5 years after the completion of study enrolment.

NCT ID: NCT03124121 Not yet recruiting - Ulcerative Colitis Clinical Trials

Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels

GO-LEVEL
Start date: July 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to gain insight into the exposure-response relationship of golimumab in moderate-to-severe Ulcerative Colitis (UC). Patients commencing induction therapy with golimumab will be enrolled into a prospective study and evaluated at three time-points (weeks 6, 10 and 14) for clinical and biochemical UC disease activity as well as serum golimumab concentrations and the presence of anti-golimumab antibodies. Patients already established on stable golimumab maintenance therapy will be enrolled into a cross-sectional study with the same evaluations taken at a single time point.

NCT ID: NCT03110289 Not yet recruiting - Ulcerative Colitis Clinical Trials

Restoration of the Microbiome Through Superdonor Selection

RESTORE-UC
Start date: April 30, 2017
Phase: N/A
Study type: Interventional

The AIM of this study is to investigate whether the FMT success rate in active UC patients can be increased by intensive donor pre-screening, anaerobic preparation of the FMT and by repeated FMT. The investigators will start a national multi-centre double-blind randomized sham-controlled trial in April 2017 at 6 hospitals in Belgium and 2 in The Netherlands. They will randomly allocate 108 patients with active ulcerative colitis (Mayo score 4-10, endoscopic Mayo score 2 or 3) in a 1:1 ratio, using a pre-established randomization list, to either 'superdonor' faecal microbiota transplantation or autologous fecal microbiota transplantation (=sham). Each patient will receive 4 FMT's. At baseline FMT will be performed during sigmoidoscopy. At week 1, 2 and 3, the FMT will be administered through rectal instillation. Each FMT will be derived from one donor. Donors will be pre-selected based on a species richness and abundance of taxa of interest. The primary outcome will be steroid-free clinical and endoscopic remission at week 8 (Mayo score ≤2, all subscores ≤ 1, and ≥1 point reduction in endoscopy subscore). Fecal, blood and mucosal samples and questionnaires will be collected at different time points. 16S rRNA stool analysis will be performed to assess the microbial changes after FMT.

NCT ID: NCT03104036 Recruiting - Ulcerative Colitis Clinical Trials

Faecal Bacteriotherapy for Ulcerative Colitis

FACTU
Start date: April 2017
Phase: Phase 2
Study type: Interventional

The etiopathogenesis of ulcerative colitis (UC) is not fully understood. One of the theories of UC pathogenesis represents a pathological response of mucosal immunity to intestinal microbiota. Potential therapeutic procedure how to affect this fact is the faecal microbiota transplantation (FMT). Review of the literature on FMT suggests great potential as the treatment for UC, but two prospective controlled study that has been published yet are inconsistent. The first objective of the project is to compare the administration of FMT enema with mesalazine enema for inducing remission in patients with active left-sided UC in the form of a prospective, randomized, controlled study. The second objective is to observe changes in the intestinal microbiota during and after FMT focusing on bacterial DNA sequencing to identify the bacterial species which are responsible for the effect of the FMT.